These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 25853461)

  • 21. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Process analytical technology (PAT) for biopharmaceutical products: Part II. Concepts and applications.
    Read EK; Shah RB; Riley BS; Park JT; Brorson KA; Rathore AS
    Biotechnol Bioeng; 2010 Feb; 105(2):285-95. PubMed ID: 19731253
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulatory environment for allergen-specific immunotherapy.
    Kaul S; May S; Lüttkopf D; Vieths S
    Allergy; 2011 Jun; 66(6):753-64. PubMed ID: 21288251
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulatory structures for gene therapy medicinal products in the European Union.
    Klug B; Celis P; Carr M; Reinhardt J
    Methods Enzymol; 2012; 507():337-54. PubMed ID: 22365782
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Registration of new medicinal products in Europe].
    Singer E
    Onkologie; 2008; 31 Suppl 2():64-6. PubMed ID: 18487872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. European Union guidance on the quality, safety and efficacy of DNA vaccines and regulatory requirements.
    Robertson JS; Cichutek K
    Dev Biol (Basel); 2000; 104():53-6. PubMed ID: 11713824
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Notes to applicants for marketing authorizations on the production and quality control of monoclonal antibodies of murine origin intended for use in man. Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy.
    Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy
    J Biol Stand; 1989 Jul; 17(3):213-22. PubMed ID: 2793873
    [No Abstract]   [Full Text] [Related]  

  • 28. Legal requirements for the quality of herbal substances and herbal preparations for the manufacturing of herbal medicinal products in the European union.
    Vlietinck A; Pieters L; Apers S
    Planta Med; 2009 Jun; 75(7):683-8. PubMed ID: 19204891
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design of experiments (DoE) in pharmaceutical development.
    N Politis S; Colombo P; Colombo G; M Rekkas D
    Drug Dev Ind Pharm; 2017 Jun; 43(6):889-901. PubMed ID: 28166428
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reflections on Decisions Made on the Well-Established Use of Medicinal Products by EU Regulators and the ECJ.
    Borg JJ; Laslop A; Pani L; Maciulaitis R; Melchiorri D
    Sci Pharm; 2014; 82(3):541-54. PubMed ID: 25853067
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quality by design for herbal drugs: a feedforward control strategy and an approach to define the acceptable ranges of critical quality attributes.
    Yan B; Li Y; Guo Z; Qu H
    Phytochem Anal; 2014; 25(1):59-65. PubMed ID: 24108478
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Process analytical technology (PAT) for biopharmaceutical products.
    Rathore AS; Bhambure R; Ghare V
    Anal Bioanal Chem; 2010 Sep; 398(1):137-54. PubMed ID: 20480150
    [TBL] [Abstract][Full Text] [Related]  

  • 33. European Regulatory guidance on virus safety of recombinant proteins, monoclonal antibodies and plasma derived medicinal products.
    Celis P; Silvester G
    Dev Biol (Basel); 2004; 118():3-10. PubMed ID: 15645667
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Guidance for performing multivariate data analysis of bioprocessing data: pitfalls and recommendations.
    Rathore AS; Mittal S; Pathak M; Arora A
    Biotechnol Prog; 2014; 30(4):967-73. PubMed ID: 24778085
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Joint EFPIA/CHMP SWP workshop: the Emerging Use of Omic Technologies for Regulatory Non-Clinical Safety Testing.
    Kasper P; Oliver G; Lima BS; Singer T; Tweats D
    Pharmacogenomics; 2005 Mar; 6(2):181-4. PubMed ID: 15882136
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FDA perspective on specifications for biotechnology products--from IND to PLA.
    Murano G
    Dev Biol Stand; 1997; 91():3-13. PubMed ID: 9413677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Implementation of "Quality by Design (QbD)" Approach for the Development of 5-Fluorouracil Loaded Thermosensitive Hydrogel.
    Dalwadi C; Patel G
    Curr Drug Deliv; 2016; 13(4):512-27. PubMed ID: 26279120
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quality by Design (QbD) Approach for a Nanoparticulate Imiquimod Formulation as an Investigational Medicinal Product.
    Pielenhofer J; Meiser SL; Gogoll K; Ciciliani AM; Denny M; Klak M; Lang BM; Staubach P; Grabbe S; Schild H; Radsak MP; Spahn-Langguth H; Langguth P
    Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Establishing a control system using QbD principles.
    Kepert JF; Cromwell M; Engler N; Finkler C; Gellermann G; Gennaro L; Harris R; Iverson R; Kelley B; Krummen L; McKnight N; Motchnik P; Schnaible V; Taticek R
    Biologicals; 2016 Sep; 44(5):319-31. PubMed ID: 27430904
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - Update: "Therapeutic options" and "Efalizumab".
    Nast A; Augustin M; Boehncke WH; Klaus J; Mrowietz U; Ockenfels HM; Philipp S; Reich K; Rosenbach T; Schlaeger M; Sebastian M; Sterry W; Streit V; Weisenseel P; Rzany B
    J Dtsch Dermatol Ges; 2010 Jan; 8(1):65-6. PubMed ID: 20096063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.